KPV Peptide: What the Evidence Shows, and What FDA Found

KPV is a three-amino-acid fragment of a natural hormone, and almost everything known about it comes from cells and mice. Those studies are real: in mouse models of colitis, oral KPV calmed gut inflammation. But when FDA reviewed it in 2026, the agency found no study of KPV in people, by any route, and no human safety data at all.^[1] KPV is not an approved drug and is not on the list of ingredients a US pharmacy may compound with. A July 2026 advisory committee vote in its favor changed nothing yet, because FDA has not acted on it.

What KPV is

KPV stands for lysine-proline-valine, the last three amino acids of alpha-melanocyte-stimulating hormone (α-MSH), a hormone made from the same precursor in the pituitary that also yields ACTH.^[1] Researchers became interested in the tail fragment in 1989, when it reduced chemically induced ear swelling in mice in a dose-related way.^[6]

The appeal was that KPV seemed to keep α-MSH’s anti-inflammatory effect without its tanning effect.^[10] How it works is still unsettled. A 2003 mouse study concluded that KPV “is unlikely to mediate its effects through melanocortin receptors,” the receptors α-MSH itself uses.^[7] FDA’s 2026 review put it more bluntly: the molecular targets behind KPV’s effects “remain unknown.”^[1]

The KPV evidence, sorted by what was actually studied

Gut inflammation: the strongest part of the case, and still mice

The gut is where KPV’s story is most developed. A 2008 study from Emory University found that KPV enters intestinal cells through PepT1, a transporter that carries small peptides and is switched on in the colon during inflammatory bowel disease. In cell lines, nanomolar amounts of KPV dampened NF-κB, a master switch for inflammatory signaling. In two mouse models of colitis, KPV given in drinking water reduced inflammation.^[8] A German group the same year reported faster recovery in two other mouse colitis models, and in mice with a broken melanocortin-1 receptor, KPV “rescued all animals in the treatment group from death.”^[9]

Later work built on that. In a mouse model of cancer that grows out of chronic colitis, KPV prevented tumors in normal mice but did nothing in mice bred without PepT1, which supports the transporter idea.^[11] Other groups have since packaged KPV in nanoparticles and gels designed to release it in the colon.^[12]

Two cautions matter for anyone reading this as a reason to take KPV for a gut problem. First, mouse colitis is created with chemicals or immune-cell transfers; it resembles human ulcerative colitis or Crohn’s disease in some ways and not in others, and many treatments that work in these models never work in people. Second, the delivery systems that worked best in the newer studies are engineered particles, not the plain capsules or vials sold online. Nobody has measured how much swallowed KPV reaches the colon in a person. Approved treatments for inflammatory bowel disease exist, and FDA noted that point in its review.^[1]

Skin and wounds: what was actually nominated

Many people meet KPV as an injection or capsule, but what a pharmacy group actually asked FDA to allow was a 0.1% cream or gel, for “wound healing and inflammatory conditions” such as psoriasis and eczema.^[1][3] The nomination cited nine papers. FDA noted that none of them studied KPV in humans; eight were animal studies of α-MSH-related peptides.^[1]

The skin data also raise a practical problem. In a lab study using donated human skin, plain KPV did not cross the skin at detectable levels; it got through only after the skin was punctured with microneedles or an electric current was applied.^[13] Dermatology researchers who favor these peptides have called them “promising future candidates” for wounds, which is another way of saying the human studies have not been done.^[14]

Does KPV help with weight loss?

There is one study, and it is in cells and mice. In a paper published online in August 2026, Korean researchers reported that KPV cut fat build-up in a mouse fat-cell line by about 55% and triglyceride content by about 38% at the highest dose. In mice fed a high-fat diet, oral KPV reduced weight gain and fat-tissue growth.^[15]

That is a first look, not evidence for a person trying to lose weight. It has not been repeated by another lab, it measured less weight gain in mice rather than weight loss, and no human has taken KPV in a trial for any purpose. Set beside the GLP-1 drugs, which have large human trials behind them, KPV is not in the same category of evidence. Our peptide menu review shows the same pattern across the other peptides that clinics sell beside GLP-1s.

What FDA found when it reviewed KPV

FDA evaluated KPV for the 503A bulks list, the list of ingredients a state-licensed pharmacy may compound with when the substance is not already in an approved drug and has no official monograph.^[4] KPV has neither.^[1] The nominating pharmacy withdrew its nomination, and FDA reviewed KPV anyway on its own initiative. Its safety-risk page now lists KPV among substances “nominated but withdrawn” from Category 2, with this note:^[2]

“FDA has not identified any human exposure data on drug products containing KPV administered via any route of administration. FDA lacks important information regarding any safety issues raised by KPV, including whether it would cause harm if administered to humans.”^[2]

— FDA, Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks

The May 2026 briefing document behind that note goes further. Among its findings:^[1]

• No toxicity testing. FDA found no acute, repeat-dose, genetic, reproductive or cancer toxicity studies of KPV.
• No adverse-event reports, which is not the same as safe. A search of FDA’s adverse event database through December 3, 2025 found none. FDA adds that pharmacies compounding under 503A generally do not report adverse events to it.
• Immune reactions are untested. Peptides can trigger antibodies and can clump into aggregates, which raises that risk. No data exist either way for KPV.
• The name does not pin down the substance. KPV is a common name with no official drug name, and FDA has seen different salts and derivatives sold under it. The nominating pharmacy’s own certificate of analysis named one form in its title and gave the chemical formula of another.
• Its conclusion: “a balancing of the criteria weighs against” adding either KPV or KPV acetate to the list.

The July 2026 vote, and KPV’s legal status now

FDA’s Pharmacy Compounding Advisory Committee took up KPV on July 23, 2026.^[3] According to trade press reports, the committee voted 8 to 6, with one abstention, to recommend BPC-157, KPV and TB-500 for the list, against the advice of FDA’s own scientists.^[16][17] FDA’s meeting page does not post a vote summary. The committee only advises: FDA is not bound by its vote, and adding a substance to the list takes notice-and-comment rulemaking.^[16][17]

Our peptide legal-status guide covers the other peptides on the same lists, and 503A vs 503B pharmacies explains the two compounding channels. BPC-157, which was voted on in the same session, has its own page: what FDA said about BPC-157.

“Research chemical” KPV: what that label means for you

Much of the KPV sold online comes in vials or capsules marked “for research use only” or “not for human consumption.” That label is not a description of who buys it. FDA’s position, set out in a December 2024 warning letter to a research-peptide seller, is that when a seller’s own website shows the products are meant for people, a “RESEARCH USE ONLY” label does not stop them being unapproved drugs.^[18]

For a buyer, the label means four things in practice:

• No prescriber and no pharmacy. Nobody has checked whether KPV suits you, and no licensed pharmacist has made or checked the product.
• No manufacturing standard. Research-grade material is not made under drug-quality rules, and FDA found no published testing standard for KPV’s impurities, clumping or microbial contamination.^[1]
• The certificate of analysis comes from the seller. Given FDA’s point that different forms of KPV are sold under one name, a seller’s own certificate is weak proof of what is in the vial.^[1]
• No dose comes from evidence. With no human studies, any dose on a label or forum is a guess.

The same reasoning applies to research-labeled GLP-1s, which we cover in buying tirzepatide as a research chemical.

If a telehealth clinic offers KPV

KPV also turns up on prescription peptide menus. Of the 153 telehealth sellers in our register with a structured peptide menu, three list KPV, often beside BPC-157 and TB-500. FDA found the same pattern online: KPV promoted as an injection, capsule, cream and nasal spray, and in “regenerative” blends with other peptides.^[1] If you are offered it, ask:

1. Which pharmacy makes it, and under what authority? KPV is not on the 503A bulks list, so a clinic naming a pharmacy should be able to explain the route.
2. What human evidence supports this use? The honest answer is none yet.
3. Which form is it, KPV or KPV acetate, and who tested it? FDA treats them as different ingredients.
4. Does my prescriber know? If you take a GLP-1 or anything else, whoever prescribes it should know what else you are using.

You can see which peptides clinics sell, and what is known about each, on our peptides hub.